Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide once weekly plus dapagliflozin versus each agent alone in type 2 diabetes inadequately controlled on metformin
2014-003503-29Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Exenatide + dapagliflozin + metformin, Exenatide + placebo + metformin and Dapagliflozin + placebo + metformin (3 arms). Primary endpoint: Change in HbA1c from baseline at 28 weeks. Started Nov 2014; status: completed.
02
Drugs
exenatidedapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-003503-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003503-29.